Abstract | BACKGROUND: The authors hypothesized that histogenetic classification of salivary duct carcinoma (SDC) could account for de novo tumors and those with morphologic or molecular evidence ( pleomorphic adenoma gene 1 [PLAG1], high-mobility group AT hook 2 [HMGA2] rearrangement, amplification) of pleomorphic adenoma (PA). METHODS: SDCs (n = 66) were reviewed for morphologic evidence of PA. PLAG1 and HMGA2 alterations were detected by fluorescence in situ hybridization (FISH). PLAG1-positive tumors were tested by FISH for fibroblast growth factor receptor 1 (FGFR1) rearrangement. Thirty-nine tumors were analyzed using a commercial panel for mutations and copy number variations in 50 cancer-related genes. RESULTS: On the basis of combined morphologic and molecular evidence of PA, 4 subsets of SDC emerged: 1) carcinomas with morphologic evidence of PA but intact PLAG1 and HMGA2 (n = 22); 2) carcinomas with PLAG1 alteration (n = 18) or 3) HMGA2 alteration (n = 12); and 4) de novo carcinomas, without morphologic or molecular evidence of PA (n = 14). The median disease-free survival was 37 months (95% confidence interval, 28.4-45.6 months). Disease-free survival and other clinicopathologic parameters did not differ for the subsets defined above. Combined Harvey rat sarcoma viral oncogene homolog/ phosphatidylinositol-4,5-biphosphate 3- kinase, catalytic subunit α (HRAS/PIK3CA) mutations were observed predominantly in de novo carcinomas (5 of 8 vs 2 of 31 tumors; P = .035). Erb-B2 receptor tyrosine kinase 2 (ERBB2) copy number gain was not observed in de novo carcinomas (0 of 8 vs 12 of 31 tumors; P = .08). Tumor protein 53 (TP53) mutations were more common in SDC ex pleomorphic adenomas than in de novo carcinomas (17 of 31 vs 1 of 8 tumors; P = .033). CONCLUSIONS: The genetic profile of SDC varies with the absence or presence of pre-existing PA and its cytogenetic signature. Most de novo SDCs harbor combined HRAS/PIK3CA mutations and no ERBB2 amplification. Cancer 2016;122:3136-44. © 2016 American Cancer Society.
|
Authors | Simion I Chiosea, Lester D R Thompson, Ilan Weinreb, Julie E Bauman, Alyssa M Mahaffey, Caitlyn Miller, Robert L Ferris, William E Gooding |
Journal | Cancer
(Cancer)
Vol. 122
Issue 20
Pg. 3136-3144
(Oct 15 2016)
ISSN: 1097-0142 [Electronic] United States |
PMID | 27379604
(Publication Type: Journal Article)
|
Copyright | © 2016 American Cancer Society. |
Chemical References |
- Biomarkers, Tumor
- DNA-Binding Proteins
- HMGA2 Protein
- PLAG1 protein, human
|
Topics |
- Adenoma, Pleomorphic
(diagnosis, genetics)
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(genetics)
- Carcinoma, Ductal
(classification, diagnosis, genetics)
- DNA-Binding Proteins
(genetics)
- Diagnosis, Differential
- Female
- Follow-Up Studies
- Gene Rearrangement
- Genetic Variation
(genetics)
- HMGA2 Protein
(genetics)
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization, Fluorescence
- Male
- Middle Aged
- Mutation
- Neoplasm Grading
- Neoplasm Staging
- Prognosis
- Salivary Gland Neoplasms
(classification, diagnosis, genetics)
- Survival Rate
|